Why Fluid Strategy Matters in Modern ICU Care1,2
Intravenous fluid resuscitation is often the first and most instinctive intervention in the management of circulatory shock. The primary objective is clear: restore intravascular volume, improve cardiac output, and reverse tissue hypoperfusion
While fluids are undeniably lifesaving during the initial “golden hour” (the first 60 minutes after the onset of shock), clinical practice has revealed a more complex reality. Increasing evidence shows that excessive or prolonged fluid administration can lead to significant complications. As a result, modern critical care is shifting away from the traditional “more is better” approach toward a more precise and disciplined model of fluid stewardship.
Risks of Excessive Fluid Administration3
A positive fluid balance is not merely a benign consequence of resuscitation; it can directly contribute to organ dysfunction. Over-resuscitation frequently leads to pulmonary edema, delayed liberation from mechanical ventilation, and impaired tissue oxygenation. The kidneys are particularly vulnerable, as fluid congestion can precipitate or worsen acute kidney injury (AKI).
Observational studies suggest that 30–50% of critically ill patients develop pathological fluid overload during their ICU stay, which has been consistently associated with increased morbidity and mortality.1
Clinical Relevance in the Indian ICU Setting2
For clinicians in India, these challenges are particularly significant due to the high burden of sepsis and septic shock in ICUs. Data from the INDICAPS multicentre registry indicate that mortality rates in septic shock cohorts in India may approach 45–50% in certain settings.2
Another important clinical concern is the high prevalence of hypoalbuminemia among critically ill patients. Evidence from tertiary care centres in India suggests that more than half of patients with sepsis present with hypoalbuminemia at ICU admission.9
Hypoalbuminemia is not simply a laboratory abnormality; it reflects a state of physiological vulnerability, often associated with increased vasopressor requirements, impaired vascular integrity, and poorer clinical outcomes.
Refining the Clinical Imperative
These observations highlight the need to reconsider how intravenous fluids are used in shock management. Fluids should no longer be viewed as inherently safe interventions administered until blood pressure stabilizes. Instead, clinicians must aim to restore e ective perfusion while minimizing the risks associated with fluid accumulation.
Albumin and the Physiology of Oncotic Support: Beyond Simple Volume Expansion4,5
Albumin plays a central role in maintaining plasma colloid oncotic pressure, thereby helping to preserve intravascular volume and vascular integrity
In septic shock, however, profound physiological disturbances occur. Systemic inflammation not only reduces hepatic albumin synthesis but also increases capillary permeability, resulting in the well-recognized capillary leak phenomenon. This process allows intravascular fluid to shift into the interstitial space, contributing to tissue edema and organ dysfunction.
Administration of human albumin therefore serves a dual purpose. In addition to expanding intravascular volume, albumin helps restore oncotic balance, enabling more sustained plasma volume expansion compared with crystalloids alone. Furthermore, emerging evidence suggests that albumin may exert anti-inflammatory, antioxidant, and endothelial-stabilizing effects, which may be particularly relevant in patients with septic shock.5
Evidence from Landmark Randomized Clinical Trials6,7
The clinical role of albumin has been evaluated in several important randomized controlled trials
The SAFE Trial:
The Saline versus Albumin Fluid Evaluation (SAFE) trial included nearly 7,000 critically ill patients and compared resuscitation with 4% albumin versus normal saline. The results demonstrated that albumin was as safe and effective as saline for fluid resuscitation. Subgroup analyses suggested a potential benefit among patients with severe sepsis.6
The ALBIOS Trial:
The Albumin Italian Outcome Sepsis (ALBIOS) trial evaluated the use of 20% albumin to maintain serum albumin levels ≥30 g/L, alongside standard crystalloid therapy in patients with severe sepsis or septic shock. While the trial did not demonstrate a significant overall mortality reduction, it did show improved hemodynamic stability and reduced vasopressor requirements in the albumin group.7
Transition to De-resuscitation: Recognizing When to Stop Fluid Expansion10
One of the most challenging aspects of shock management is not initiating fluid resuscitation but recognizing the appropriate time to limit further fluid administration.
As the patient stabilizes, the therapeutic goal must shift from aggressive volume expansion to optimization of fluid balance and prevention of fluid overload. This transition—known as de-resuscitation is a critical component of modern fluid stewardship
Clinicians must identify the clinical “tipping point” at which additional fluid ceases to improve perfusion and instead contributes to tissue congestion and organ dysfunction.
Identifying the Window for Fluid Removal
Indicators that a patient may be ready for active fluid management include:
- Metabolic recovery: decreasing lactate levels and improving acid–base balance
- Vasopressor weaning: progressive reduction in vasopressor support
- Adequate organ perfusion: sustained urine output
- Hemodynamic stability: stable blood pressure and heart rate without escalating support
At the bedside, tools such as point-of-care ultrasound (POCUS) and dynamic hemodynamic monitoring can assist clinicians in determining whether additional fluid administration will improve cardiac output or merely worsen tissue congestion.10
Active Strategies for Restoring Fluid Balance11
Once hemodynamic stability has been achieved, the focus should shift toward active fluid removal and restoration of physiological balance.
Key strategies include:
Fluid Restriction
Limiting unnecessary maintenance fluids and avoiding non-essential intravenous infusions.
Diuretic Therapy
Loop diuretics are typically the first-line option in patients with preserved renal function to achieve a negative fluid balance.
Controlled Ultrafiltration
In patients with severe or persistent fluid overload—particularly when renal function is impaired—renal replacement therapy with ultrafiltration allows precise and gradual fluid removal while maintaining organ perfusion.11
The Future of ICU Care: Phase-Based Fluid Stewardship12
Shock management should not be viewed as a single intervention but rather as a dynamic process that evolves throughout the course of critical illness.
Failure to recognize the transition from necessary resuscitation to harmful fluid accumulation remains a common challenge in ICU practice. Persistent positive fluid balance has been strongly associated with pulmonary edema, impaired organ function, and increased mortality.
To address this challenge, many experts advocate a phase-based approach to fluid therapy, commonly described using the ROSE model:
- Resuscitation – rapid restoration of perfusion
- Optimization – adjustment of hemodynamics
- Stabilization – maintenance of organ perfusion
- De-resuscitation – active removal of excess fluid
This framework emphasizes that intravenous fluids should be treated as a therapeutic intervention requiring continuous reassessment, rather than administered reflexively
Where Albumin Fits Within the Fluid Stewardship Framework
Within this phase-based model, albumin-containing solutions can play an important role during the optimization and stabilization phases of shock management.
In patients requiring significant intravascular support, albumin may help achieve hemodynamic targets with smaller fluid volumes, thereby reducing the cumulative crystalloid burden that contributes to tissue edema.
Albumin may be particularly useful in situations where clinicians approach the “crystalloid ceiling,” beyond which additional crystalloid administration offers limited benefit while increasing the risk of fluid overload.12
By scanning the code, you will be directed to an external website which is owned and managed by Takeda
Flexbumin®
